Kamran Alam - Feb 2, 2023 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
Chief Financial Officer
Signature
/s/ Kamran Alam
Stock symbol
TSHA
Transactions as of
Feb 2, 2023
Transactions value $
$0
Form type
4
Date filed
2/6/2023, 08:12 PM
Previous filing
Aug 24, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Award +18.7K +7.02% 285K Feb 2, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Employee Stock Option (right to buy) Award $0 +37.4K $0.00 37.4K Feb 2, 2023 Common Stock 37.4K $1.18 Direct F3
transaction TSHA Employee Stock Option (right to buy) Award $0 +150K $0.00 150K Feb 2, 2023 Common Stock 150K $1.18 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. 12,461 RSUs shall vest 25% on each of February 2, 2024, February 2, 2025, February 2, 2026 and February 2, 2027. The remaining RSUs, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
F2 Each RSU represents a contingent right to receive one share the Issuer's common stock.
F3 24,923 shares underlying the option shall vest 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter. The remaining shares underlying the option, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
F4 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.